← Back to Screener
Syndax Pharmaceuticals, Inc. (SNDX)
Price$23.81
Favorite Metrics
Price vs S&P 500 (26W)43.47%
Price vs S&P 500 (4W)-2.95%
Market Capitalization$2.15B
All Metrics
Book Value / Share (Quarterly)$0.74
P/TBV (Annual)2.31x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)-44.66%
Cash Flow / Share (Quarterly)$-3.70
Price vs S&P 500 (YTD)13.16%
Gross Margin (TTM)95.96%
Net Profit Margin (TTM)-165.37%
EPS (TTM)$-3.30
10-Day Avg Trading Volume1.39M
EPS Excl Extra (TTM)$-3.30
Revenue Growth (5Y)158.26%
EPS (Annual)$-3.29
ROI (Annual)-69.86%
Gross Margin (Annual)95.96%
Net Profit Margin (5Y Avg)-2021.44%
Cash / Share (Quarterly)$4.73
Revenue Growth QoQ (YoY)794.90%
ROA (Last FY)-53.88%
Revenue Growth TTM (YoY)628.88%
EBITD / Share (TTM)$-3.17
ROE (5Y Avg)-123.17%
Operating Margin (TTM)-158.22%
Cash Flow / Share (Annual)$-3.70
P/B Ratio33.23x
P/B Ratio (Quarterly)28.25x
Net Income / Employee (Annual)$-1
EV / Revenue (TTM)13.65x
Net Interest Coverage (TTM)-24.82x
ROA (TTM)-49.25%
EV / EBITDA (TTM)1540.30x
EPS Incl Extra (Annual)$-3.29
Current Ratio (Annual)4.40x
Quick Ratio (Quarterly)4.04x
3-Month Avg Trading Volume1.40M
52-Week Price Return116.46%
Revenue / Employee (TTM)$1
Tangible BV / Share (Quarterly)$5.16
P/S Ratio (Annual)12.46x
Asset Turnover (Annual)0.33x
52-Week High$25.59
Operating Margin (5Y Avg)-2033.49%
EPS Excl Extra (Annual)$-3.29
Tangible BV CAGR (5Y)34.98%
26-Week Price Return47.45%
Quick Ratio (Annual)4.04x
13-Week Price Return17.42%
Total Debt / Equity (Annual)5.32x
Current Ratio (Quarterly)4.40x
Enterprise Value$2,356.665
Revenue / Share Growth (5Y)122.73%
Asset Turnover (TTM)0.30x
Book Value / Share Growth (5Y)-32.47%
Revenue / Employee (Annual)$1
Pretax Margin (Annual)-165.60%
Cash / Share (Annual)$4.73
3-Month Return Std Dev42.65%
Net Income / Employee (TTM)$-1
ROE (Last FY)-441.62%
Net Interest Coverage (Annual)-24.82x
EPS Basic Excl Extra (Annual)$-3.29
Receivables Turnover (TTM)7.57x
Total Debt / Equity (Quarterly)5.32x
EPS Incl Extra (TTM)$-3.30
ROI (TTM)-59.13%
P/S Ratio (TTM)12.44x
Pretax Margin (5Y Avg)-2021.44%
Revenue / Share (Annual)$1.99
Tangible BV / Share (Annual)$6.86
Price vs S&P 500 (52W)86.63%
Year-to-Date Return15.80%
5-Day Price Return-1.74%
EPS Normalized (Annual)$-3.29
ROA (5Y Avg)-31.30%
Net Profit Margin (Annual)-165.60%
Month-to-Date Return4.15%
Cash Flow / Share (TTM)$-2.59
EBITD / Share (Annual)$-3.17
Operating Margin (Annual)-158.45%
LT Debt / Equity (Annual)5.32x
ROI (5Y Avg)-36.84%
LT Debt / Equity (Quarterly)5.32x
EPS Basic Excl Extra (TTM)$-3.30
P/TBV (Quarterly)3.01x
P/B Ratio (Annual)28.25x
Inventory Turnover (TTM)0.42x
Pretax Margin (TTM)-165.37%
Book Value / Share (Annual)$0.74
Price vs S&P 500 (13W)16.74%
Beta0.53x
P/FCF (Annual)74.06x
Revenue / Share (TTM)$1.99
ROE (TTM)-206.62%
52-Week Low$8.58
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.35
4.35
4.35
4.35
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
SNDXSyndax Pharmaceuticals, Inc. | 12.44x | 628.88% | 95.96% | — | $23.81 |
LLYEli Lilly & Co. | 13.08x | 44.70% | 83.04% | 27.59% | $903.99 |
JNJJohnson & Johnson | 5.94x | 7.87% | 67.95% | 14.90% | $234.54 |
ABBVABBVIE INC. | 6.04x | 8.57% | 71.62% | -2.88% | $208.99 |
MRKMerck & Co., Inc. | 4.41x | 1.31% | 78.55% | 21.23% | $115.46 |
AZNAstraZeneca PLC | 5.28x | 8.63% | 81.31% | 21.88% | $200.47 |
NVSNovartis AG | 4.98x | 8.91% | 75.82% | 15.26% | $149.73 |
NVONovo-Nordisk A/S | 3.62x | 6.43% | 80.98% | 20.66% | $40.93 |
ABTAbbott Laboratories | 3.66x | 6.59% | 56.50% | 8.20% | $95.47 |
PFEPfizer Inc. | 2.47x | -1.64% | 75.81% | -3.51% | $27.22 |
BMYBristol-Myers Squibb Co. | 2.47x | -0.22% | 72.63% | — | $58.96 |
About
Syndax Pharmaceuticals is a clinical-stage biopharmaceutical company developing targeted therapies for cancer and immune-related diseases. Its pipeline includes revumenib, a selective menin-MLL inhibitor for acute leukemias; axatilimab, a CSF-1R antibody for chronic graft-versus-host disease and pulmonary fibrosis; and entinostat, an oral small molecule targeting cancer cells and immune cells. The company is based in the United States.